Literature DB >> 26686335

Occupational radiation exposure of medical staff performing ⁹⁰Y-loaded microsphere radioembolization.

Sophie Laffont1, Yan Rolland2, Valérie Ardisson1, Julien Edeline3,4,5, Marc Pracht4, Samuel Le Sourd4, Tanguy Rohou2, Laurence Lenoir1, Nicolas Lepareur1,5, Etienne Garin6,7,8.   

Abstract

PURPOSE: Radioembolization of liver cancer with (90)Y-loaded microspheres is increasingly used but data regarding hospital staff exposure are scarce. We evaluated the radiation exposure of medical staff while preparing and injecting (90)Y-loaded glass and resin microspheres especially in view of the increasing use of these products.
METHODS: Exposure of the chest and finger of the radiopharmacist, nuclear medicine physician and interventional radiologist during preparation and injection of 78 glass microsphere preparations and 16 resin microsphere preparations was monitored. Electronic dosimeters were used to measure chest exposure and ring dosimeters were used to measure finger exposure.
RESULTS: Chest exposure was very low for both products used (<10 μSv from preparation and injection). In our experience, finger exposure was significantly lower than the annual limit of 500 mSv for both products. With glass microspheres, the mean finger exposure was 13.7 ± 5.2 μSv/GBq for the radiopharmacist, and initially 17.9 ± 5.4 μSv/GBq for the nuclear medicine physician reducing to 13.97 ± 7.9 μSv/GBq with increasing experience. With resin microspheres, finger exposure was more significant: mean finger exposure for the radiopharmacist was 295.1 ± 271.9 μSv/GBq but with a reduction with increasing experience to 97.5 ± 35.2 μSv/GBq for the six most recent dose preparations. For administration of resin microspheres, the greatest mean finger exposure for the nuclear medicine physician (the most exposed operator) was 235.5 ± 156 μSv/GBq.
CONCLUSION: Medical staff performing (90)Y-loaded microsphere radioembolization procedures are exposed to safe levels of radiation. Exposure is lower than that from treatments using (131)I-lipiodol. The lowest finger exposure is from glass microspheres. With resin microspheres finger exposure is acceptable but could be optimized in accordance with the ALARA principle, and especially in view of the increasing use of radioembolization.

Entities:  

Keywords:  90Y; Exposure; Microspheres; Radioembolization

Mesh:

Substances:

Year:  2015        PMID: 26686335     DOI: 10.1007/s00259-015-3277-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  11 in total

1.  Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.

Authors:  Etienne Garin; Laurence Lenoir; Yan Rolland; Julien Edeline; Habiba Mesbah; Sophie Laffont; Philippe Porée; Bruno Clément; Jean-Luc Raoul; E Boucher
Journal:  J Nucl Med       Date:  2012-02       Impact factor: 10.057

2.  Improvements in extremity dose assessment for ionising radiation medical applications.

Authors:  M Ginjaume; S Pérez; X Ortega
Journal:  Radiat Prot Dosimetry       Date:  2007-02-03       Impact factor: 0.972

3.  Exposure of medical personnel to radiation during radionuclide therapy practices.

Authors:  Sophie Lancelot; Benjamin Guillet; Sophie Sigrist; Marc Bourrelly; Serge Waultier; Oliver Mundler; Pascale Pisano
Journal:  Nucl Med Commun       Date:  2008-04       Impact factor: 1.690

4.  Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.

Authors:  B Gray; G Van Hazel; M Hope; M Burton; P Moroz; J Anderson; V Gebski
Journal:  Ann Oncol       Date:  2001-12       Impact factor: 32.976

5.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

6.  Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.

Authors:  Riad Salem; Robert J Lewandowski; Mary F Mulcahy; Ahsun Riaz; Robert K Ryu; Saad Ibrahim; Bassel Atassi; Talia Baker; Vanessa Gates; Frank H Miller; Kent T Sato; Ed Wang; Ramona Gupta; Al B Benson; Steven B Newman; Reed A Omary; Michael Abecassis; Laura Kulik
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

7.  Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering 131I-lipiodol therapy for hepatocellular carcinoma.

Authors:  E Garin; S Laffont; Y Rolland; D Olivie; J Lecloirec; J-Y Herry; E Boucher; J-L Raoul; P Bourguet
Journal:  Nucl Med Commun       Date:  2003-06       Impact factor: 1.690

8.  Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.

Authors:  Maarten L J Smits; Johannes F W Nijsen; Maurice A A J van den Bosch; Marnix G E H Lam; Maarten A D Vente; Willem P T M Mali; Alfred D van Het Schip; Bernard A Zonnenberg
Journal:  Lancet Oncol       Date:  2012-08-22       Impact factor: 41.316

9.  International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.

Authors:  Patricia Bernal; Jean-Luc Raoul; Janez Stare; Erdenechimeg Sereegotov; Felix X Sundram; Ajay Kumar; Jae-Min Jeong; Pawana Pusuwan; Chaitanya Divgi; Pat Zanzonico; Gaj Vidmar; John Buscombe; Trinh Thi Minh Chau; Maung Maung Saw; Shaoliang Chen; Ruben Ogbac; Maurizio Dondi; Ajit Kumar Padhy
Journal:  Semin Nucl Med       Date:  2008-03       Impact factor: 4.446

10.  Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

Authors:  E Garin; L Lenoir; J Edeline; S Laffont; H Mesbah; P Porée; L Sulpice; K Boudjema; M Mesbah; A Guillygomarc'h; E Quehen; M Pracht; J L Raoul; B Clement; Y Rolland; E Boucher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-24       Impact factor: 9.236

View more
  3 in total

Review 1.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

2.  Epidemic characteristics and related risk factors of occupational exposure for pediatric health care workers in Chinese public hospitals: a cross-sectional study.

Authors:  Yuanshuo Ma; Xin Ni; Yu Shi; Chunmei Yan; Lei Shi; Zhe Li; Xiangxu Gao; Dinan Wang; Xi Yang; Lihua Fan; Yongchen Wang
Journal:  BMC Public Health       Date:  2019-11-05       Impact factor: 3.295

3.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  M Weber; M Lam; C Chiesa; M Konijnenberg; M Cremonesi; P Flamen; S Gnesin; L Bodei; T Kracmerova; M Luster; E Garin; K Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-11       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.